Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Rapid Influenza Diagnostic Tests Evaluated

By LabMedica International staff writers
Posted on 05 Sep 2012
Recent outbreaks of influenza have underscored the need to validate the accuracy of rapid influenza diagnostic tests (RIDTs) routinely used in clinical settings

The accuracy of seven commercially available tests have been checked as negative results from RIDTs for influenza A (H3N2v) should not be considered reliable evidence of lack of infection. More...

The US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) checked the seven RIDTs using seven different H3N2v viral strains. H3N2v viruses can be detected by qualified public health laboratories using the CDC Flu Real-Time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) Diagnostic Panel for A(H3N2)v (CDC Flu rRT-PCR Dx). Five 10-fold dilutions in physiological saline of each virus grown in Madin-Darby Canine Kidney (MDCK) cells were tested with all of the RIDTs in duplicate.

Tests with BinaxNOW Influenza A&B (Alere; Waltham, MA, USA), Directigen EZ Flu A+B (Becton-Dickinson; Franklin Lakes, NJ, USA), SAS FluAlert A&B (SA Scientific; San Antonio, TX, USA), QuickVue Influenza A+B Test and Sofia Influenza A+B (Quidel; San Diego, CA, USA) were performed according to the procedures in the kit inserts for nasal washes or aspirates. Xpect Flu A&B (Remel; Lenexa, KS, USA) tests were performed according to their procedure for nasal washes and swab specimens transported in liquid media. For the BD Veritor System for Rapid Detection of Flu A+B (Becton Dickinson) test, 100 µL of diluted specimen was added directly to the reagent tube.

Positive and negative controls contained in each RIDT were run before testing the viruses in the study to verify performance of each assay lot, with the exception of FluAlert, which does not provide controls. The CDC reports that only four of the seven RIDTs tested, Directigen, Sofia, Veritor, and Xpect, detected all seven of the H3N2v strains. The BinaxNOW test spotted five of the seven strains, and the QuickVue test found three of the seven. The FluAlert test detected only one of the viral samples in this test.

In this evaluation of seven RIDTs, the ability to detect H3N2v virus varied substantially among the tests. This evaluation emphasizes the fact that a negative RIDT result should not be considered as conclusive evidence of lack of infection with influenza A (H3N2)v. More data are needed on the clinical performance of all RIDTs in detecting H3N2v virus in various respiratory specimens. Results from RIDTs, both positive and negative, always should be interpreted in the broader context of the circulating influenza strains present in the area, level of clinical suspicion, severity of illness, and risk for complications in a patient with suspected infection. The study was published on August 17, 2012, in the journal Morbidity and Mortality Weekly Report (MMWR).

Related Links:
US Centers for Disease Control and Prevention




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.